Result of General Meeting

BiVictriX Therapeutics PLC

29 August 2024

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018. With the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.

NOT FOR PUBLICATION OR RELEASE IN OR INTO THE UNITED STATES OR AUSTRALIA, CANADA, JAPAN, NEW ZEALAND, THE REPUBLIC OF IRELAND OR THE REPUBLIC OF SOUTH AFRICA, OR ANY PROVINCE OR TERRITORY THEREOF OR TO OR FOR THE ACCOUNT OF ANY NATIONAL, RESIDENT OR CITIZEN OF THE UNITED STATES OR ANY PERSON RESIDENT IN AUSTRALIA, CANADA, JAPAN, NEW ZEALAND, THE REPUBLIC OF IRELAND OR THE REPUBLIC OF SOUTH AFRICA.

BiVictriX Therapeutics plc

("BiVictriX", "BiVictriX Therapeutics" or the "Company")

Result of General Meeting

Alderley Park, 29 August 2024 - BiVictriX (AIM: BVX), a drug discovery and development company applying an innovative, proprietary approach to develop a new class of highly selective, next generation cancer therapeutics, bispecific antibody drug conjugates (Bi-Cygni® ADCs), which exhibit superior potency, whilst reducing treatment-related toxicities, announces that at the Company's General Meeting ("General Meeting") held earlier today, all resolutions put to the Company's shareholders ("Shareholders") were duly passed.

Details of proxy votes received are summarised below:

Resolution Number	Resolution Name	Votes For		Votes Against
		No. of shares	% of shares voted	No. of shares	% of shares voted
1	Cancellation Resolution	56,143,735	99.86	80,108	0.14
2	Re-registration Resolution and Adoption of New Articles of Association	56,143,735	99.86	80,108	0.14

The full text of the resolutions proposed and passed at the General Meeting can be found in the circular containing, inter alia, the Notice of General Meeting, which was published and posted to Shareholders on 12 August 2024 and is available on the Company's website https://bivictrix.com (the "Circular").

AIM Delisting

Following approval by Shareholders at the General Meeting, the admission of the ordinary shares of £0.01 each in the capital of the Company ("Ordinary Shares") to trading on AIM will be cancelled (the "AIM Delisting"). The AIM Delisting is expected to take place at 7:00 a.m on 11 September 2024 ("Cancellation") and, accordingly, the last day of dealings in Ordinary Shares on AIM is expected to be 10 September 2024.

Re-registration as a private company

In accordance with the passing of Resolution 2, the Company will re-register as a private limited company and adopt new articles of association, which is expected to take place in the week commencing 23 September 2024.

Matched Bargain Facility

To facilitate future shareholder transactions in the Company's Ordinary Shares, the Company has appointed JP Jenkins to provide a matched bargain facility, which will be available upon the date of Cancellation. Upon Cancellation, full details of the matched bargain facility will be made available to Shareholders  on the Company's website https://bivictrix.com.

Capitalised terms used but not defined in this announcement shall have the same meaning given to such terms in the Circular.

For more information, please contact:

BiVictriX Therapeutics plc Tiffany Thorn, Chief Executive Officer Michael Kauffman, Non-Executive Chairman	Email: [e-mail]
SP Angel Corporate Finance LLP (NOMAD and Broker) David Hignell, Caroline Rowe (Corporate Finance) Vadim Alexandre, Rob Rees (Sales and Broking)	Tel: [phone]
Panmure Liberum Limited (Joint Broker) Emma Earl, Freddy Crossley, Mark Rogers, Rupert Dearden	Tel: [phone]
ICR Consilium       Namrata Taak, Lucy Featherstone, Max Bennett, Emmalee Hoppe	Tel: [phone] Email: [e-mail]

About BiVictriX Therapeutics plc

BiVictriX (AIM: BVX) is an emerging biotechnology company leveraging clinical experience and its proprietary discovery engine to advance a new class of highly cancer-selective, next-generation precision cancer therapies in one of the fastest-growing markets in oncology. BiVictriX's first-in-class Bi-Cygni® Antibody Drug Conjugates ("ADCs") combine superior efficacy with substantially improved cancer-selectivity and safety to provide opportunities for prolonged dosing and greater efficacy in the clinic. The Company is advancing its pipeline to deliver the future of cancer care across a broad range of haematological and solid cancer indications in areas of high unmet medical need.

Find out more at www.bivictrix.com and connect with us on LinkedIn and Twitter @BiVictriX.

 

END